Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.08 USD
Change Today -0.01 / -0.92%
Volume 290.5K
BIOD On Other Exchanges
BIOD is not on other exchanges.
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BIOD) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/14 - $2.56
52 Week Low
04/15/15 - $0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIODEL INC (BIOD)

Related News

No related news articles were found.

biodel inc (BIOD) Related Businessweek News

No Related Businessweek News Found

biodel inc (BIOD) Details

Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

30 Employees
Last Reported Date: 12/19/14
Founded in 2003

biodel inc (BIOD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $688.4K
Chief Medical Officer
Total Annual Compensation: $437.0K
Chief Administrative Officer, Vice President ...
Total Annual Compensation: $334.2K
Compensation as of Fiscal Year 2014.

biodel inc (BIOD) Key Developments

Biodel Inc. Announces the Results from A Formative Human Factors Study of its Glucagon Emergency Management

Biodel Inc. announced results from a formative human factors study of its Glucagon Emergency Management (GEM) device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits (Eli Lilly's Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen(R) HypoKit(TM)). The average time to dose delivery was 48% faster with the GEM device compared to the marketed glucagon kits (76.3 seconds vs. 113.4 seconds; p(0.05). The formative human factors study was designed to compare the usability and performance of the GEM device to the current marketed glucagon kits (Eli Lilly's Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen(R) HypoKit(TM)) under simulated emergency conditions and to determine the impact of previous experience with the glucagon kits and training. The first group consisted of eight caregivers of diabetic patients and first responders, all of whom were familiar with through prior training and/or experience at least one of the marketed glucagon kits. The second group consisted of eight caregivers of diabetic patients and first responders who were naive to the marketed glucagon kits. The third group consisted of eight adults with no relationship to a diabetes patient who were naive to the marketed glucagon kits.

Biodel Mulls Acquisitions

Biodel Inc. (NasdaqCM:BIOD) is looking for acquisitions. Biodel Inc. has filed a follow-on equity offering and intends to use the net proceeds from this offering for operating costs, capital expenditures and for general corporate purposes, including working capital. Biodel Inc. may also use a portion of the net proceeds to invest in or acquire businesses or technologies that are complementary to their own.

Biodel Inc. Approves Amendment to the Second Amended and Restated Certificate of Incorporation

Biodel Inc. at its annual meeting of stockholders 2015 held on March 17, 2015, approved the amendment to the company's Second Amended and Restated Certificate of Incorporation, as amended, to effect an increase in the number of shares of authorized common stock, par value $0.01 per share, from 62,500,000 shares to 200,000,000 shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOD:US $1.08 USD -0.01

BIOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOD.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at